Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 373-376

  Yang, Li ^a   Wei, Ling ^a   Zhao, Wei ^a   Wang, Xingwu ^a   Zheng, Gang ^a   Zheng, Meizhu ^a   Song, Xianrang ^a   Zuo, Wenshu ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast neoplasms; Chemotherapy sensitivity; Osteopontin; RNA interference

Indexed keywords

DOXORUBICIN; MESSENGER RNA; OSTEOPONTIN; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SENESCENCE; CELLULAR PARAMETERS; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOPONTIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84862934553     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.679     Document Type: Article

References (23)

1. Beausoleil MS, Schulze EB, Goodale D, Postenka CO and Allan AL: Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer 11: 25, 2011.
2. Denhardt D, Lopez C, Rollo E, Hwang S, An X and Walther S: Osteopontin-induced modifications of cellular functions. Ann NY Acad Sci 760: 127-142, 1995.
3. Zhang Z, Vuori K, Reed JC and Ruoslahti E: The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92: 6161-6165, 1995.
4. Ding Q, Stewart JJ, Prince C, et al: Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 62: 5336-5343, 2002. (Pubitemid 35024610)
5. Senger D, Perruzzi C, Gracey C, Papadopoulos A and Tenen D: Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 48: 5770-5774, 1988.
6. Singhal H, Bautista D, Tonkin K, O'Malley F, Tuck A, Chambers AH and Harris JFR: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997. (Pubitemid 27211840)
7. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658-1667, 1999. (Pubitemid 29102494)
8. Behera R, Kumar V, Lohite K, Karnik S and Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 31: 192-200, 2010.
9. Noti JD: Adherence to osteopontin via αvβ3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-α. Int J Oncol 17: 1237.1243, 2000.
10. He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25: 2192-2202, 2006.
11. Hedley BD, Welch DR, Allan AL, et al: Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 123: 526-534, 2008. (Pubitemid 351898409)
12. Wang S, Liu Q, Zhang Y, et al: Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol Cancer 8: 81, 2009.
13. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H and Bache M: Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 5: 82, 2010.
14. Ihnen M, Wirtz RM, Kalogeras KT, et al: Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer 103: 1048-1056, 2010.
15. Das S, Samant RS and Shevde LA: Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J Biol Chem 286: 9612-9622, 2011.
16. El-Tanani MK, Yuen HF, Shi Z, et al: Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells. Cancer Sci 101: 1354-1360, 2010.
17. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ and Kuo PC: Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 32: 477-487, 2011.
18. Gu T, Ohashi R, Cui R, et al: Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 66: 176-183, 2009.
19. Shevde LA, Samant RS, Paik JC, et al: Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23: 123-133, 2006. (Pubitemid 44440172)
20. Aoudjit F and Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20: 4995-5004, 2001. (Pubitemid 32769789)
21. Graessmann M, Berg B, Fuchs B, Klein A and Graessmann A: Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 26: 2840-2850, 2007. (Pubitemid 46701443)
22. Allan AL, George R, Vantyghem SA, et al: Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169: 233-246, 2006.
23. Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB and Fan Z: Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin, and gemcitabine. Mol Pharmacol 70: 1045-1052, 2006. (Pubitemid 44268461)